0.05Open0.05Pre Close0 Volume40 Open Interest1.00Strike Price0.00Turnover72.86%IV3.26%PremiumJan 17, 2025Expiry Date0.02Intrinsic Value100Multiplier7DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.5424Delta3.8655Gamma19.66Leverage Ratio-0.0027Theta-0.0001Rho-10.66Eff Leverage0.0006Vega
CytomX Stock Discussion
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
Monday, 6th January at 4:05 pm
- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 -
- Early-stage research and platform capabilities to be concentrated on existing and potential future partnerships dur...
Dow Jones· 1 min ago
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
📊⚡️📊
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
No comment yet